| pubmed-article:1981038 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1981038 | lifeskim:mentions | umls-concept:C0023977 | lld:lifeskim |
| pubmed-article:1981038 | lifeskim:mentions | umls-concept:C0149721 | lld:lifeskim |
| pubmed-article:1981038 | lifeskim:mentions | umls-concept:C0232804 | lld:lifeskim |
| pubmed-article:1981038 | lifeskim:mentions | umls-concept:C0003015 | lld:lifeskim |
| pubmed-article:1981038 | lifeskim:mentions | umls-concept:C0014025 | lld:lifeskim |
| pubmed-article:1981038 | lifeskim:mentions | umls-concept:C0085580 | lld:lifeskim |
| pubmed-article:1981038 | lifeskim:mentions | umls-concept:C0205082 | lld:lifeskim |
| pubmed-article:1981038 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1981038 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1981038 | pubmed:dateCreated | 1991-3-28 | lld:pubmed |
| pubmed-article:1981038 | pubmed:abstractText | The therapeutic effect of long-term enalapril administration was studied in 20 patients with severe essential hypertension (EH), resistant to intensive therapy with a combination of 3 or 4 antihypertensive drugs. Addition of enalapril (Renitec MSD from 5 to 40 mg/day) to the previous therapy allowed to maintain blood pressure within limits not exceeding 150/95 mmHg during a 12-month study in more than 80% of previously resistant patients. Left ventricular hypertrophy regressed in all patients and dilatation of the left ventricle seen in 4 patients disappeared during enalapril treatment. Serum sodium creatinine did not change significantly. Serum potassium increased slightly but remained within the normal range. Proteinuria had a tendency to diminish and N-acetyl-beta-D-glucosaminidase activity in the urine dropped within normal limits. Based on their results, the authors conclude that enalapril is suitable for the long-term treatment of patients with severe EH, resistant to intensive antihypertensive therapy, with minimal side effects, good tolerance and a tendency for amelioration of cardiac and renal function. | lld:pubmed |
| pubmed-article:1981038 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1981038 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1981038 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1981038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1981038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1981038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1981038 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1981038 | pubmed:issn | 0010-8650 | lld:pubmed |
| pubmed-article:1981038 | pubmed:author | pubmed-author:SimonB MBM | lld:pubmed |
| pubmed-article:1981038 | pubmed:author | pubmed-author:HorkýKK | lld:pubmed |
| pubmed-article:1981038 | pubmed:author | pubmed-author:KrálJJ | lld:pubmed |
| pubmed-article:1981038 | pubmed:author | pubmed-author:WidimskýJJJr | lld:pubmed |
| pubmed-article:1981038 | pubmed:author | pubmed-author:HánaVV | lld:pubmed |
| pubmed-article:1981038 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1981038 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:1981038 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1981038 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1981038 | pubmed:pagination | 353-62 | lld:pubmed |
| pubmed-article:1981038 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:meshHeading | pubmed-meshheading:1981038-... | lld:pubmed |
| pubmed-article:1981038 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1981038 | pubmed:articleTitle | The effect of long-term treatment by the angiotensin I-converting enzyme inhibitor enalapril on renal function and left ventricular hypertrophy in severe essential hypertension. | lld:pubmed |
| pubmed-article:1981038 | pubmed:affiliation | Laboratory for Endocrinology, Charles University School of Medicine, Prague, Czechoslovakia. | lld:pubmed |
| pubmed-article:1981038 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1981038 | pubmed:publicationType | Clinical Trial | lld:pubmed |
